ArticleFrontiers in psychology2015
A new cognitive evaluation battery for Down syndrome and its relevance for clinical trials.
Article in Frontiers in psychology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03624556 (Pediatric Exploratory Research Study of EGCG Use and Safety), which is not on this map. Cited by 41 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Pediatric Exploratory Research Study of EGCG Use and Safety (PERSEUS)
Who cites it
41 citing papers in PubMed, 1 synthesis or guideline pooled it, 69 citations in OpenAlex.
- Assessing general cognitive and adaptive abilities in adults with Down syndrome: a systematic review.Journal of neurodevelopmental disorders · 2019Pooled it
- Adaptive and Maladaptive Behaviours and Their Cognitive Correlates in Aging Adults With Down Syndrome.Journal of applied research in intellectual disabilities : JARID · 2026Article
- Distinct brain regions are affected by neurodevelopmental or pre-dementia changes in Down syndrome.Brain communications · 2026Article
- Baseline Neuropsychological Characteristics of Adolescents and Young Adults with Down Syndrome Who Participated in Two Clinical Trials of the Drug Memantine.Brain sciences · 2025Article
- Sex-related differences in genetically determined Alzheimer's disease.Frontiers in aging neuroscience · 2025Review
- Investigating brain alterations in the Dp1Tyb mouse model of Down syndrome.Neurobiology of disease · 2023Article
- Cognitive flexibility assessment in youth with Down syndrome: Reliability, practice effects, and validity.Research in developmental disabilities · 2023Article
- Predisposition to atherosclerosis in children and adults with trisomy 21: biochemical and metabolomic studies.Pediatric endocrinology, diabetes, and metabolism · 2023Article
- The association between expressive language skills and adaptive behavior in individuals with Down syndrome.Scientific reports · 2022Article
- The innate immune system stimulating cytokine GM-CSF improves learning/memory and interneuron and astrocyte brain pathology in Dp16 Down syndrome mice and improves learning/memory in wild-type mice.Neurobiology of disease · 2022Article
- Article
- Article
- Relationship between Apgar scores and long-term cognitive outcomes in individuals with Down syndrome.Scientific reports · 2021Article
- Complexity Analysis of the Default Mode Network Using Resting-State fMRI in Down Syndrome: Relationships Highlighted by a Neuropsychological Assessment.Brain sciences · 2021Article
- Opportunities, barriers, and recommendations in down syndrome research.Translational science of rare diseases · 2021Article
- Markers of early changes in cognition across cohorts of adults with Down syndrome at risk of Alzheimer's disease.Alzheimer's & dementia (Amsterdam, Netherlands) · 2021Article
- Adaptation of the Clinical Dementia Rating Scale for adults with Down syndrome.Journal of neurodevelopmental disorders · 2019Article
- Trisomy 21 activates the kynurenine pathway via increased dosage of interferon receptors.Nature communications · 2019Article
- New approaches to studying early brain development in Down syndrome.Developmental medicine and child neurology · 2019Review
- Association of Dementia With Mortality Among Adults With Down Syndrome Older Than 35 Years.JAMA neurology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 9 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The recent prospect of pharmaceutical interventions for cognitive impairment of Down syndrome (DS) has boosted a number of clinical trials in this population. However, running the trials has raised some methodological challenges and questioned the prevailing methodology used to evaluate cognitive functioning of DS individuals. This is usually achieved by comparing DS individuals to matched healthy controls of the same mental age. We propose a new tool, the TESDAD Battery that uses comparison with age-matched typically developed adults. This is an advantageous method for probing the clinical efficacy of DS therapies, allowing the interpretation and prediction of functional outcomes in clinical trials. In our DS population the TESDAD battery permitted a quantitative assessment of cognitive defects, which indicated language dysfunction and deficits in executive function, as the most important contributors to other cognitive and adaptive behavior outcomes as predictors of functional change in DS. Concretely, auditory comprehension and functional academics showed the highest potential as end-point measures of therapeutic intervention for clinical trials: the former as a cognitive key target for therapeutic intervention, and the latter as a primary functional outcome measure of clinical efficacy. Our results also emphasize the need to explore the modulating effects of IQ, gender and age on cognitive enhancing treatments. Noticeably, women performed significantly better than men of the same age and IQ in most cognitive tests, with the most consistent differences occurring in memory and executive functioning and negative trends rarely emerged on quality of life linked to the effect of age after adjusting for IQ and gender. In sum, the TESDAD battery is a useful neurocognitive tool for probing the clinical efficacy of experimental therapies in interventional studies in the DS population suggesting that age-matched controls are advantageous for determining normalization of DS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.